down arrow

Ginkgo Bioworks Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US37611X1000
USD
8.24
0.00 (0.00%)

Dec 18

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.188.90

52 Week

5.0017.50
Valuation
Technical
Day's Volume

CASH

1.04 M

Shareholding (Mar 2025)

FII

24.20%

Held by 124 FIIs

DII

55.42%

Held by 21 DIIs

Promoter

3.41%

How big is Ginkgo Bioworks Holdings, Inc.?

22-Jun-2025

As of Jun 18, Ginkgo Bioworks Holdings, Inc. has a market capitalization of 500.45 million, with net sales of 237.43 million and a net profit of -472.07 million over the latest four quarters. The company reported shareholder's funds of 716.06 million and total assets of 1,377.45 million as of Dec 24.

Market Cap: As of Jun 18, Ginkgo Bioworks Holdings, Inc. has a market capitalization of 500.45 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ginkgo Bioworks reported net sales of 237.43 million and a net profit of -472.07 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 716.06 million and total assets of 1,377.45 million.

Read More

What does Ginkgo Bioworks Holdings, Inc. do?

22-Jun-2025

Ginkgo Bioworks Holdings, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $48 million and a net loss of $91 million as of March 2025. Key metrics include a market cap of $500.45 million, a P/E ratio of NA, and a debt-to-equity ratio of -0.81.

Overview: <BR>Ginkgo Bioworks Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 48 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -91 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 500.45 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.81 <BR>Return on Equity: -60.42% <BR>Price to Book: 0.77<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Ginkgo Bioworks Holdings, Inc. overvalued or undervalued?

20-Sep-2025

As of August 16, 2021, Ginkgo Bioworks Holdings, Inc. is considered a risky investment due to its negative P/E ratio, significant losses reflected in a -60.42% ROE, and poor valuation metrics compared to peers, despite a strong 1-year stock return of 54.12%.

As of 16 August 2021, the valuation grade for Ginkgo Bioworks Holdings, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued, given its negative P/E ratio and significant losses reflected in its ROE of -60.42%. Key valuation ratios include a Price to Book Value of 0.69, an EV to EBIT of 0.21, and an EV to EBITDA of 0.25, all of which suggest that the company is struggling to generate positive returns relative to its valuation metrics.<BR><BR>In comparison to peers, Ginkgo Bioworks has a worse EV to EBITDA ratio than Agilon Health, which stands at -0.6626, further highlighting its relative weakness in the industry. Despite a strong 1-year stock return of 54.12% compared to the S&P 500's 17.14%, the company's long-term performance over 3 years shows a dramatic decline of -90.45%, indicating significant volatility and risk.

Read More

Is Ginkgo Bioworks Holdings, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Ginkgo Bioworks Holdings, Inc. has a mildly bullish technical outlook, supported by a bullish weekly MACD and moving averages, despite a recent 11.5% decline, while outperforming the S&P 500 with a 79.54% return over the past year.

As of 10 October 2025, the technical trend for Ginkgo Bioworks Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the KST shows a mildly bearish trend on both weekly and monthly time frames. The Dow Theory supports a mildly bullish outlook for both weekly and monthly periods. <BR><BR>In terms of returns, Ginkgo Bioworks has outperformed the S&P 500 significantly over the past year, with a return of 79.54% compared to the S&P 500's 13.36%. However, it experienced a sharp decline of 11.5% over the past week, while the S&P 500 fell only 2.43%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from MACD, moving averages, and Dow Theory.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -274.96% of over the last 5 years

 
2

Risky - Negative EBITDA

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 662 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.79

stock-summary
Return on Equity

-49.94%

stock-summary
Price to Book

1.08

Revenue and Profits:
Net Sales:
50 Million
(Quarterly Results - Jun 2025)
Net Profit:
-60 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.85%
0%
-27.85%
6 Months
-3.96%
0%
-3.96%
1 Year
-6.26%
0%
-6.26%
2 Years
-86.96%
0%
-86.96%
3 Years
376.3%
0%
376.3%
4 Years
-98.16%
0%
-98.16%
5 Years
0%
0%
0.0%

Ginkgo Bioworks Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Ginkgo Bioworks Holdings, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance

Ginkgo Bioworks Holdings, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance

Ginkgo Bioworks Holdings, Inc. has recently seen a stock price adjustment, currently at $13.16. Over the past year, the company has achieved a remarkable 79.54% return, significantly surpassing the S&P 500. Various technical indicators suggest a mixed outlook, reflecting the company's resilience in the Pharmaceuticals & Biotechnology sector.

Read More

Is Ginkgo Bioworks Holdings, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Ginkgo Bioworks Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the KST shows a mildly bearish trend on both weekly and monthly time frames. The Dow Theory supports a mildly bullish outlook for both weekly and monthly periods. In terms of returns, Ginkgo Bioworks has outperformed the S&P 500 significantly over the past year, with a return of 79.54% compared to the S&P 500's 13.36%. However, it experienced a sharp decline of 11.5% over the past week, while the S&P 500 fell only 2.43%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from MACD, moving averages, and Dow Theory....

Read More

Is Ginkgo Bioworks Holdings, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Ginkgo Bioworks Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive but weakening momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the KST shows a mildly bearish signal on both weekly and monthly time frames, which adds some caution. The Dow Theory confirms a mildly bullish trend on both weekly and monthly levels. In terms of performance, Ginkgo Bioworks has significantly outperformed the S&P 500 over the past year with an 88.3% return compared to the S&P's 13.36%. Over three years, the stock has returned 367.82% versus the S&P's 81.39%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from MACD, moving averages, and Dow Theory....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-13.46%
EBIT Growth (5y)
-274.96%
EBIT to Interest (avg)
-826.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0.27
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.64%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.69
EV to EBIT
0.21
EV to EBITDA
0.25
EV to Capital Employed
-0.66
EV to Sales
-0.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-60.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 45 Schemes (16.98%)

Foreign Institutions

Held by 124 Foreign Institutions (24.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 2.69% vs 10.27% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 33.74% vs 15.35% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "49.60",
          "val2": "48.30",
          "chgp": "2.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-52.60",
          "val2": "-70.50",
          "chgp": "25.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.60",
          "val2": "-1.50",
          "chgp": "273.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-60.30",
          "val2": "-91.00",
          "chgp": "33.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,379.20%",
          "val2": "-1,778.10%",
          "chgp": "39.89%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -9.74% vs -47.35% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 38.74% vs 57.61% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "227.00",
          "val2": "251.50",
          "chgp": "-9.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-397.30",
          "val2": "-600.70",
          "chgp": "33.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-114.60",
          "val2": "-187.00",
          "chgp": "38.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-547.00",
          "val2": "-892.90",
          "chgp": "38.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,027.40%",
          "val2": "-2,673.40%",
          "chgp": "64.60%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
49.60
48.30
2.69%
Operating Profit (PBDIT) excl Other Income
-52.60
-70.50
25.39%
Interest
0.00
0.00
Exceptional Items
2.60
-1.50
273.33%
Consolidate Net Profit
-60.30
-91.00
33.74%
Operating Profit Margin (Excl OI)
-1,379.20%
-1,778.10%
39.89%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 2.69% vs 10.27% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 33.74% vs 15.35% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
227.00
251.50
-9.74%
Operating Profit (PBDIT) excl Other Income
-397.30
-600.70
33.86%
Interest
0.10
0.10
Exceptional Items
-114.60
-187.00
38.72%
Consolidate Net Profit
-547.00
-892.90
38.74%
Operating Profit Margin (Excl OI)
-2,027.40%
-2,673.40%
64.60%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -9.74% vs -47.35% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 38.74% vs 57.61% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Ginkgo Bioworks Holdings, Inc. stock-summary
stock-summary
Ginkgo Bioworks Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."